(Q45395440)

14 December 2017

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years (English)

1 reference

14 December 2017

1 reference

1 reference

C L Cooper

1

1 reference

14 December 2017

J B Angel

2

1 reference

14 December 2017

I Seguin

3

1 reference

14 December 2017

H L Davis

4

1 reference

14 December 2017

D W Cameron

5

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Clinical Infectious Diseases

14 December 2017

1 reference

14 December 2017

46

1 reference

14 December 2017

1310-1314

1 reference

14 December 2017

8

1 reference

Outcome of Hepatitis B Virus Infection in Homosexual Men and Its Relation to Prior Human Immunodeficiency Virus Infection

14 December 2017

1 reference

Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule

21 January 2018

1 reference

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

21 January 2018

1 reference

Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children

21 January 2018

1 reference

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

21 January 2018

1 reference

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

21 January 2018

1 reference

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/533467

1 reference

14 December 2017

1 reference